Stay updated on MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page shows a revision update from v3.6.4 to v3.6.5, signaling a small maintenance/update. It does not change study details or visible content.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page revision was updated to v3.6.4, replacing the previous v3.6.3, indicating a new version of the study page.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision tag updated from v3.6.2 to v3.6.3, indicating a newer version of the page.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page revision changed from v3.6.0 to v3.6.2, signaling a backend version update. No user-facing content or behavior was modified.SummaryDifference0.1%

- Check74 days agoChange DetectedRecruitment status updated to not currently enrolling participants. New navigation sections—How to Read a Study Record, Common Questions, and How to Join a Study—were added, and the Intervention/Treatment heading formatting was updated along with the revision label from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check82 days agoChange DetectedThe page’s revision number was updated from v3.5.4 to v3.5.5, signaling a backend release with no impact on the study data or user-facing information.SummaryDifference0.1%

Stay in the know with updates to MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.